Effects of Three Acepromazine Doses on the Incidence of Morphine-Induced Vomiting, Sedation and Some Physiological Variables in Dogs

Background: Acepromazine was found to reduce the incidence of vomiting induced by opioids such as morphine, hydromorphone and oxymorphone in dogs. Despite the effectiveness of the phenothiazine in preventing opioid-induced vomiting in this species, a single dose of acepromazine (0.05 mg/kg) was tested and the influence of dose on the antiemetic effect of the drug is unknown. The primary objective of this study was to evaluate the effect of three acepromazine doses on the incidence of vomiting induced by morphine in dogs. A secondary aim was to assess the degree of sedation and effects on physiological variables following administration of the combinations tested.Materials, Methods & Results: All dogs received 0.5 mg/kg morphine (IM). Fifteen min before morphine, dogs in the Control, ACPLD, ACPMD and ACPHD groups were administered (IM) physiological saline or acepromazine at doses of 0.025, 0.05 and 0.1 mg/kg, respectively. In Phase 1, purpose-bred dogs (n = 8) underwent each of the four treatments in a randomized, crossover design; the incidence of vomiting, sedation, pulse rate (PR), systolic, mean and diastolic blood pressures (SAP, MAP and DAP) were investigated for 60 min. Sedation was assessed by a numeric descriptive scale (NDS, range 0-3) and a simple numerical scale (SNS, range 1-10). In Phase 2, client-owned dogs (n = 50) received a single treatment and only the in

Effects of Three Acepromazine Doses on the Incidence of Morphine-Induced Vomiting, Sedation and Some Physiological Variables in Dogs

Background: Acepromazine was found to reduce the incidence of vomiting induced by opioids such as morphine, hydromorphone and oxymorphone in dogs. Despite the effectiveness of the phenothiazine in preventing opioid-induced vomiting in this species, a single dose of acepromazine (0.05 mg/kg) was tested and the influence of dose on the antiemetic effect of the drug is unknown. The primary objective of this study was to evaluate the effect of three acepromazine doses on the incidence of vomiting induced by morphine in dogs. A secondary aim was to assess the degree of sedation and effects on physiological variables following administration of the combinations tested.Materials, Methods & Results: All dogs received 0.5 mg/kg morphine (IM). Fifteen min before morphine, dogs in the Control, ACPLD, ACPMD and ACPHD groups were administered (IM) physiological saline or acepromazine at doses of 0.025, 0.05 and 0.1 mg/kg, respectively. In Phase 1, purpose-bred dogs (n = 8) underwent each of the four treatments in a randomized, crossover design; the incidence of vomiting, sedation, pulse rate (PR), systolic, mean and diastolic blood pressures (SAP, MAP and DAP) were investigated for 60 min. Sedation was assessed by a numeric descriptive scale (NDS, range 0-3) and a simple numerical scale (SNS, range 1-10). In Phase 2, client-owned dogs (n = 50) received a single treatment and only the in

Effects of Three Acepromazine Doses on the Incidence of Morphine-Induced Vomiting, Sedation and Some Physiological Variables in Dogs

Background: Acepromazine was found to reduce the incidence of vomiting induced by opioids such as morphine, hydromorphone and oxymorphone in dogs. Despite the effectiveness of the phenothiazine in preventing opioid-induced vomiting in this species, a single dose of acepromazine (0.05 mg/kg) was tested and the influence of dose on the antiemetic effect of the drug is unknown. The primary objective of this study was to evaluate the effect of three acepromazine doses on the incidence of vomiting induced by morphine in dogs. A secondary aim was to assess the degree of sedation and effects on physiological variables following administration of the combinations tested.Materials, Methods & Results: All dogs received 0.5 mg/kg morphine (IM). Fifteen min before morphine, dogs in the Control, ACPLD, ACPMD and ACPHD groups were administered (IM) physiological saline or acepromazine at doses of 0.025, 0.05 and 0.1 mg/kg, respectively. In Phase 1, purpose-bred dogs (n = 8) underwent each of the four treatments in a randomized, crossover design; the incidence of vomiting, sedation, pulse rate (PR), systolic, mean and diastolic blood pressures (SAP, MAP and DAP) were investigated for 60 min. Sedation was assessed by a numeric descriptive scale (NDS, range 0-3) and a simple numerical scale (SNS, range 1-10). In Phase 2, client-owned dogs (n = 50) received a single treatment and only the in

Effects of Three Acepromazine Doses on the Incidence of Morphine-Induced Vomiting, Sedation and Some Physiological Variables in Dogs

Background: Acepromazine was found to reduce the incidence of vomiting induced by opioids such as morphine, hydromorphone and oxymorphone in dogs. Despite the effectiveness of the phenothiazine in preventing opioid-induced vomiting in this species, a single dose of acepromazine (0.05 mg/kg) was tested and the influence of dose on the antiemetic effect of the drug is unknown. The primary objective of this study was to evaluate the effect of three acepromazine doses on the incidence of vomiting induced by morphine in dogs. A secondary aim was to assess the degree of sedation and effects on physiological variables following administration of the combinations tested.Materials, Methods & Results: All dogs received 0.5 mg/kg morphine (IM). Fifteen min before morphine, dogs in the Control, ACPLD, ACPMD and ACPHD groups were administered (IM) physiological saline or acepromazine at doses of 0.025, 0.05 and 0.1 mg/kg, respectively. In Phase 1, purpose-bred dogs (n = 8) underwent each of the four treatments in a randomized, crossover design; the incidence of vomiting, sedation, pulse rate (PR), systolic, mean and diastolic blood pressures (SAP, MAP and DAP) were investigated for 60 min. Sedation was assessed by a numeric descriptive scale (NDS, range 0-3) and a simple numerical scale (SNS, range 1-10). In Phase 2, client-owned dogs (n = 50) received a single treatment and only the in

Effects of Three Acepromazine Doses on the Incidence of Morphine-Induced Vomiting, Sedation and Some Physiological Variables in Dogs

Background: Acepromazine was found to reduce the incidence of vomiting induced by opioids such as morphine, hydromorphone and oxymorphone in dogs. Despite the effectiveness of the phenothiazine in preventing opioid-induced vomiting in this species, a single dose of acepromazine (0.05 mg/kg) was tested and the influence of dose on the antiemetic effect of the drug is unknown. The primary objective of this study was to evaluate the effect of three acepromazine doses on the incidence of vomiting induced by morphine in dogs. A secondary aim was to assess the degree of sedation and effects on physiological variables following administration of the combinations tested.Materials, Methods & Results: All dogs received 0.5 mg/kg morphine (IM). Fifteen min before morphine, dogs in the Control, ACPLD, ACPMD and ACPHD groups were administered (IM) physiological saline or acepromazine at doses of 0.025, 0.05 and 0.1 mg/kg, respectively. In Phase 1, purpose-bred dogs (n = 8) underwent each of the four treatments in a randomized, crossover design; the incidence of vomiting, sedation, pulse rate (PR), systolic, mean and diastolic blood pressures (SAP, MAP and DAP) were investigated for 60 min. Sedation was assessed by a numeric descriptive scale (NDS, range 0-3) and a simple numerical scale (SNS, range 1-10). In Phase 2, client-owned dogs (n = 50) received a single treatment and only the in

Effects of Three Acepromazine Doses on the Incidence of Morphine-Induced Vomiting, Sedation and Some Physiological Variables in Dogs

Background: Acepromazine was found to reduce the incidence of vomiting induced by opioids such as morphine, hydromorphone and oxymorphone in dogs. Despite the effectiveness of the phenothiazine in preventing opioid-induced vomiting in this species, a single dose of acepromazine (0.05 mg/kg) was tested and the influence of dose on the antiemetic effect of the drug is unknown. The primary objective of this study was to evaluate the effect of three acepromazine doses on the incidence of vomiting induced by morphine in dogs. A secondary aim was to assess the degree of sedation and effects on physiological variables following administration of the combinations tested.Materials, Methods & Results: All dogs received 0.5 mg/kg morphine (IM). Fifteen min before morphine, dogs in the Control, ACPLD, ACPMD and ACPHD groups were administered (IM) physiological saline or acepromazine at doses of 0.025, 0.05 and 0.1 mg/kg, respectively. In Phase 1, purpose-bred dogs (n = 8) underwent each of the four treatments in a randomized, crossover design; the incidence of vomiting, sedation, pulse rate (PR), systolic, mean and diastolic blood pressures (SAP, MAP and DAP) were investigated for 60 min. Sedation was assessed by a numeric descriptive scale (NDS, range 0-3) and a simple numerical scale (SNS, range 1-10). In Phase 2, client-owned dogs (n = 50) received a single treatment and only the in

Comparison of the sedative effects of morphine, meperidine or fentanyl, in combination with acepromazine, in dogs

This study aimed to compare the sedative effects of morphine, meperidine and fentanyl, in combination with acepromazine (ACP) and their effects on physiologic values in dogs. Six healthy beagle dogs were randomly assigned to four treatments with 7-day washout intervals. In three treatments, ACP (0.05mg kg-1) was administered and 20 minutes later, the dogs received administration of 0.5mg kg-1 of morphine (ACPMOR), 5mg kg-1 of meperidine (ACPMEP) or 5µg kg-1 of fentanyl (ACPFEN). In treatment ACP HD MOR, 0.1mg kg-1 of ACP was administered in combination with 0.5mg kg-1 of morphine. All drugs were administered intravenously. Sedation scores were evaluated by a numeric descriptive scale (NDS: 0-3) and a simple numeric scale (SNS: 0-10). All variables were evaluated for 120 minutes. The administration of ACP caused mild to moderate sedation. Sedation was improved in all treatments after opioid administration, but significant differences were detected only in ACPMOR and ACP HD MOR. More dogs presented intense sedation (NDS=3.0) after administration of morphine (3/6 and 4/6 dogs in ACPMOR and ACP HD MOR versus 1/6 in other treatments). Duration of sedation was longer in ACPMOR and ACP HD MOR. Mild to moderate decreases in blood pressure, respiratory rate and temperature were observed in all treatments but decreased HR was observed only in ACPMOR and ACP HD MOR. No significant differences were observed in the aforementioned variables when twice the dose of ACP was used (treatment ACP HD MOR). Under the conditions of this study, administration of morphine, in combination with ACP, results in greater and longer sedation than meperidine and fentanyl. Increasing the dose of ACP, in combination with morphine, does not improve the degree of sedation. All combinations used were considered to be safe for healthy dogs.

O presente estudo objetivou comparar o efeito sedativo da morfina, meperidina e fentanil associados à acepromazina (ACP) e seus efeitos sobre as variáveis fisiológicas de cães. Seis cães Beagle hígidos foram aleatoriamente submetidos a quatro tratamentos com intervalo de 7 dias. Em três tratamentos, foi administrada ACP (0,05mg kg-1) e, após 20 minutos, 0,5mg kg-1 de morfina (ACPMOR), 5mg kg-1 de meperidina (ACPMEP) ou 5µg kg-1 de fentanil (ACPFEN). No tratamento ACP DA MOR, a dose de 0,1mg kg-1 de ACP foi associada a 0,5mg kg-1 de morfina. Todos os fármacos foram administrados pela via IV. Escores de sedação foram avaliados pela escala numérica descritiva (END: 0-3) e escala numérica simples (ENS: 0-10). Todas as variáveis foram avaliadas durante 120 minutos. A administração da ACP causou sedação leve à moderada. A sedação foi intensificada em todos os tratamentos após a administração do opioide, mas diferença significativa foi observada somente em ACPMOR e ACP DA MOR. Um número maior de cães apresentou sedação intensa (END=3,0) após a administração da morfina (3/6 e 4/6 cães em ACPMOR e ACP DA MOR versus 1/6 nos demais tratamentos). A duração do efeito sedativo foi mais longa em ACPMOR e ACP DA MOR. Houve redução leve a moderada na pressão arterial, frequência respiratória e temperatura em todos os tratamentos e redução significativa da frequência cardíaca somente nos tratamentos ACPMOR e ACP DA MOR. Não houve diferenças significativas nas variáveis estudadas quando o dobro da dose de ACP foi utilizada (tratamento ACP DA MOR). Nas condições deste estudo, a administração da morfina, em associação à ACP, resulta em sedação de maior intensidade e duração do que a meperidina e o fentanil. O aumento na dose de ACP, em associação à morfina, não intensifica o grau de sedação. Todas as associações foram consideradas seguras para cães hígidos.

Influence of acepromazine on the cardiovascular actions of dobutamine in isoflurane-anesthetized horses

The influence of acepromazine (ACP) on the effectiveness of dobutamine (DBT) in increasing blood pressure during isoflurane (ISO) anesthesia was evaluated in six horses. On separate occasions, the horses were randomly assigned to receive NaCl 0.9% (Control), ACP 0.025mg kg-1 and ACP 0.05mg kg-1. The experimental treatment was administered prior to induction of anesthesia. Maintenance of anesthesia was performed under conditions of normocapnia with ISO in oxygen. Dobutamine was administered at progressively increasing infusion rates until mean arterial pressure (MAP) reached 70mmHg or until a maximum infusion rate of 5.0µg kg-1 min-1. Compared with baseline, DBT increased heart rate, systolic, diastolic and mean blood pressures in all treatments. However, these variables did not differ among treatments. The target MAP (70mmHg) was not reached in 2/6, 2/5 and 0/6 horses in the Control, ACP0.025 and ACP0.05 treatments, respectively. The mean dose of DBT to achieve target MAP was 3.5±1.8, 3.7±1.6 and 2.7±1.4µg kg-1 min-1 in the Control, ACP0.025 and ACP0.05 treatments, respectively (P>0.05). Under the conditions of this study, premedication with ACP does not interfere with the effectiveness of DBT in increasing blood pressure in horses anesthetized with ISO.

A influência da acepromazina (ACP) sobre a capacidade da dobutamina (DBT) em elevar a pressão arterial durante a anestesia com isofluorano (ISO) foi avaliada em seis equinos. Em ocasiões diferentes, os animais receberam aleatoriamente NaCl 0,9% (Controle), ACP 0,025mg kg-1 e ACP 0,05mg kg-1. O tratamento experimental foi administrado previamente à indução da anestesia. A manutenção da anestesia foi realizada em condições de normocapnia com ISO em oxigênio. A administração de DBT foi iniciada em doses progressivamente crescentes até que o valor de pressão arterial média (PAM) atingisse 70mmHg ou até a dose máxima de 5,0µg kg-1 min-1. Comparado ao basal, a administração da DBT resultou em elevação na frequência cardíaca e pressões arteriais sistólica, diastólica e média em todos os tratamentos. Porém, não houve diferença entre os tratamentos nessas variáveis. A PAM alvo (70mmHg) não foi atingida em 2/6, 2/5 e 0/6 animais dos tratamentos Controle, ACP0.025 e ACP0.05, respectivamente. A dose média de DBT para a PAM alvo foi de 3,5±1,8; 3,7±1,6 e 2,7±1,4µg kg-1 min-1 no Controle, ACP0.025 e ACP0.05, respectivamente (P>0,05). Nas condições deste estudo, o pré-tratamento com ACP não interfere na eficácia da DBT em elevar a pressão arterial de cavalos anestesiados com ISO.

Comparison of the sedative effects of morphine, meperidine or fentanyl, in combination with acepromazine, in dogs

This study aimed to compare the sedative effects of morphine, meperidine and fentanyl, in combination with acepromazine (ACP) and their effects on physiologic values in dogs. Six healthy beagle dogs were randomly assigned to four treatments with 7-day washout intervals. In three treatments, ACP (0.05mg kg-1) was administered and 20 minutes later, the dogs received administration of 0.5mg kg-1 of morphine (ACPMOR), 5mg kg-1 of meperidine (ACPMEP) or 5µg kg-1 of fentanyl (ACPFEN). In treatment ACP HD MOR, 0.1mg kg-1 of ACP was administered in combination with 0.5mg kg-1 of morphine. All drugs were administered intravenously. Sedation scores were evaluated by a numeric descriptive scale (NDS: 0-3) and a simple numeric scale (SNS: 0-10). All variables were evaluated for 120 minutes. The administration of ACP caused mild to moderate sedation. Sedation was improved in all treatments after opioid administration, but significant differences were detected only in ACPMOR and ACP HD MOR. More dogs presented intense sedation (NDS=3.0) after administration of morphine (3/6 and 4/6 dogs in ACPMOR and ACP HD MOR versus 1/6 in other treatments). Duration of sedation was longer in ACPMOR and ACP HD MOR. Mild to moderate decreases in blood pressure, respiratory rate and temperature were observed in all treatments but decreased HR was observed only in ACPMOR and ACP HD MOR. No significant differences were observed in the aforementioned variables when twice the dose of ACP was used (treatment ACP HD MOR). Under the conditions of this study, administration of morphine, in combination with ACP, results in greater and longer sedation than meperidine and fentanyl. Increasing the dose of ACP, in combination with morphine, does not improve the degree of sedation. All combinations used were considered to be safe for healthy dogs.

O presente estudo objetivou comparar o efeito sedativo da morfina, meperidina e fentanil associados à acepromazina (ACP) e seus efeitos sobre as variáveis fisiológicas de cães. Seis cães Beagle hígidos foram aleatoriamente submetidos a quatro tratamentos com intervalo de 7 dias. Em três tratamentos, foi administrada ACP (0,05mg kg-1) e, após 20 minutos, 0,5mg kg-1 de morfina (ACPMOR), 5mg kg-1 de meperidina (ACPMEP) ou 5µg kg-1 de fentanil (ACPFEN). No tratamento ACP DA MOR, a dose de 0,1mg kg-1 de ACP foi associada a 0,5mg kg-1 de morfina. Todos os fármacos foram administrados pela via IV. Escores de sedação foram avaliados pela escala numérica descritiva (END: 0-3) e escala numérica simples (ENS: 0-10). Todas as variáveis foram avaliadas durante 120 minutos. A administração da ACP causou sedação leve à moderada. A sedação foi intensificada em todos os tratamentos após a administração do opioide, mas diferença significativa foi observada somente em ACPMOR e ACP DA MOR. Um número maior de cães apresentou sedação intensa (END=3,0) após a administração da morfina (3/6 e 4/6 cães em ACPMOR e ACP DA MOR versus 1/6 nos demais tratamentos). A duração do efeito sedativo foi mais longa em ACPMOR e ACP DA MOR. Houve redução leve a moderada na pressão arterial, frequência respiratória e temperatura em todos os tratamentos e redução significativa da frequência cardíaca somente nos tratamentos ACPMOR e ACP DA MOR. Não houve diferenças significativas nas variáveis estudadas quando o dobro da dose de ACP foi utilizada (tratamento ACP DA MOR). Nas condições deste estudo, a administração da morfina, em associação à ACP, resulta em sedação de maior intensidade e duração do que a meperidina e o fentanil. O aumento na dose de ACP, em associação à morfina, não intensifica o grau de sedação. Todas as associações foram consideradas seguras para cães hígidos.

Influence of acepromazine on the cardiovascular actions of dobutamine in isoflurane-anesthetized horses

The influence of acepromazine (ACP) on the effectiveness of dobutamine (DBT) in increasing blood pressure during isoflurane (ISO) anesthesia was evaluated in six horses. On separate occasions, the horses were randomly assigned to receive NaCl 0.9% (Control), ACP 0.025mg kg-1 and ACP 0.05mg kg-1. The experimental treatment was administered prior to induction of anesthesia. Maintenance of anesthesia was performed under conditions of normocapnia with ISO in oxygen. Dobutamine was administered at progressively increasing infusion rates until mean arterial pressure (MAP) reached 70mmHg or until a maximum infusion rate of 5.0µg kg-1 min-1. Compared with baseline, DBT increased heart rate, systolic, diastolic and mean blood pressures in all treatments. However, these variables did not differ among treatments. The target MAP (70mmHg) was not reached in 2/6, 2/5 and 0/6 horses in the Control, ACP0.025 and ACP0.05 treatments, respectively. The mean dose of DBT to achieve target MAP was 3.5±1.8, 3.7±1.6 and 2.7±1.4µg kg-1 min-1 in the Control, ACP0.025 and ACP0.05 treatments, respectively (P>0.05). Under the conditions of this study, premedication with ACP does not interfere with the effectiveness of DBT in increasing blood pressure in horses anesthetized with ISO.

A influência da acepromazina (ACP) sobre a capacidade da dobutamina (DBT) em elevar a pressão arterial durante a anestesia com isofluorano (ISO) foi avaliada em seis equinos. Em ocasiões diferentes, os animais receberam aleatoriamente NaCl 0,9% (Controle), ACP 0,025mg kg-1 e ACP 0,05mg kg-1. O tratamento experimental foi administrado previamente à indução da anestesia. A manutenção da anestesia foi realizada em condições de normocapnia com ISO em oxigênio. A administração de DBT foi iniciada em doses progressivamente crescentes até que o valor de pressão arterial média (PAM) atingisse 70mmHg ou até a dose máxima de 5,0µg kg-1 min-1. Comparado ao basal, a administração da DBT resultou em elevação na frequência cardíaca e pressões arteriais sistólica, diastólica e média em todos os tratamentos. Porém, não houve diferença entre os tratamentos nessas variáveis. A PAM alvo (70mmHg) não foi atingida em 2/6, 2/5 e 0/6 animais dos tratamentos Controle, ACP0.025 e ACP0.05, respectivamente. A dose média de DBT para a PAM alvo foi de 3,5±1,8; 3,7±1,6 e 2,7±1,4µg kg-1 min-1 no Controle, ACP0.025 e ACP0.05, respectivamente (P>0,05). Nas condições deste estudo, o pré-tratamento com ACP não interfere na eficácia da DBT em elevar a pressão arterial de cavalos anestesiados com ISO.

Radiografia quantitativa hepática de cães tranquilizados com acepromazina

The acepromazine is one of the most commonly tranquilizer used in veterinary medicine and its use may cause splenomegaly. However it is not known if it can cause hepatomegaly. The aim of this study is to evaluate the quantitative radiography with digital assistance to determine the liver size and volume of dogs tranquilized with acepromazine. Nine healthy dogs were radiographed in the lateral right and ventral-dorsal liver , before and after intramuscular administration of acepromazine at a dose of 0.1kg-1. It was possible to characterize the size and increase in liver size (P 0.05) between the different experimental moments with a strong positive correlation between the measures liver assets. The quantitative radiographic technique used in this study accurately characterized the increase in size and volume of the liver in dogs treated with acepromazine.

O maleato de acepromazina é um dos tranquilizantes mais utilizados em medicina veterinária, podendo causar esplenomegalia, mas não é conhecida a possibilidade de ocorrência de hepatomegalia. Objetivou-se, com o presente estudo, utilizar a radiografia quantitativa com auxilio digital para determinar o tamanho e volume do fígado de cães tranquilizados com acepromazina. Foram radiografados, na projeção lateral direita e ventrodorsal do fígado, nove cães hígidos, antes e após a administração intramuscular de maleato de acepromazina, na dose de 0,1mg kg-1 de peso. Foi possível caracterizar aumento das dimensões hepáticas (P 0,05) entre os diferentes momentos experimentais com forte correlação positiva entre as medidas corpóreas. A técnica radiográfica quantitativa empregada neste estudo caracterizou com precisão o aumento de tamanho e volume hepático nos cães tratados com acepromazina.

Radiografia quantitativa hepática de cães tranquilizados com acepromazina

The acepromazine is one of the most commonly tranquilizer used in veterinary medicine and its use may cause splenomegaly. However it is not known if it can cause hepatomegaly. The aim of this study is to evaluate the quantitative radiography with digital assistance to determine the liver size and volume of dogs tranquilized with acepromazine. Nine healthy dogs were radiographed in the lateral right and ventral-dorsal liver , before and after intramuscular administration of acepromazine at a dose of 0.1kg-1. It was possible to characterize the size and increase in liver size (P 0.05) between the different experimental moments with a strong positive correlation between the measures liver assets. The quantitative radiographic technique used in this study accurately characterized the increase in size and volume of the liver in dogs treated with acepromazine.

O maleato de acepromazina é um dos tranquilizantes mais utilizados em medicina veterinária, podendo causar esplenomegalia, mas não é conhecida a possibilidade de ocorrência de hepatomegalia. Objetivou-se, com o presente estudo, utilizar a radiografia quantitativa com auxilio digital para determinar o tamanho e volume do fígado de cães tranquilizados com acepromazina. Foram radiografados, na projeção lateral direita e ventrodorsal do fígado, nove cães hígidos, antes e após a administração intramuscular de maleato de acepromazina, na dose de 0,1mg kg-1 de peso. Foi possível caracterizar aumento das dimensões hepáticas (P 0,05) entre os diferentes momentos experimentais com forte correlação positiva entre as medidas corpóreas. A técnica radiográfica quantitativa empregada neste estudo caracterizou com precisão o aumento de tamanho e volume hepático nos cães tratados com acepromazina.

Influence of acepromazine on the cardiovascular actions of dobutamine in isoflurane-anesthetized horses

The influence of acepromazine (ACP) on the effectiveness of dobutamine (DBT) in increasing blood pressure during isoflurane (ISO) anesthesia was evaluated in six horses. On separate occasions, the horses were randomly assigned to receive NaCl 0.9% (Control), ACP 0.025mg kg-1 and ACP 0.05mg kg-1. The experimental treatment was administered prior to induction of anesthesia. Maintenance of anesthesia was performed under conditions of normocapnia with ISO in oxygen. Dobutamine was administered at progressively increasing infusion rates until mean arterial pressure (MAP) reached 70mmHg or until a maximum infusion rate of 5.0µg kg-1 min-1. Compared with baseline, DBT increased heart rate, systolic, diastolic and mean blood pressures in all treatments. However, these variables did not differ among treatments. The target MAP (70mmHg) was not reached in 2/6, 2/5 and 0/6 horses in the Control, ACP0.025 and ACP0.05 treatments, respectively. The mean dose of DBT to achieve target MAP was 3.5±1.8, 3.7±1.6 and 2.7±1.4µg kg-1 min-1 in the Control, ACP0.025 and ACP0.05 treatments, respectively (P>0.05). Under the conditions of this study, premedication with ACP does not interfere with the effectiveness of DBT in increasing blood pressure in horses anesthetized with ISO.

A influência da acepromazina (ACP) sobre a capacidade da dobutamina (DBT) em elevar a pressão arterial durante a anestesia com isofluorano (ISO) foi avaliada em seis equinos. Em ocasiões diferentes, os animais receberam aleatoriamente NaCl 0,9% (Controle), ACP 0,025mg kg-1 e ACP 0,05mg kg-1. O tratamento experimental foi administrado previamente à indução da anestesia. A manutenção da anestesia foi realizada em condições de normocapnia com ISO em oxigênio. A administração de DBT foi iniciada em doses progressivamente crescentes até que o valor de pressão arterial média (PAM) atingisse 70mmHg ou até a dose máxima de 5,0µg kg-1 min-1. Comparado ao basal, a administração da DBT resultou em elevação na frequência cardíaca e pressões arteriais sistólica, diastólica e média em todos os tratamentos. Porém, não houve diferença entre os tratamentos nessas variáveis. A PAM alvo (70mmHg) não foi atingida em 2/6, 2/5 e 0/6 animais dos tratamentos Controle, ACP0.025 e ACP0.05, respectivamente. A dose média de DBT para a PAM alvo foi de 3,5±1,8; 3,7±1,6 e 2,7±1,4µg kg-1 min-1 no Controle, ACP0.025 e ACP0.05, respectivamente (P>0,05). Nas condições deste estudo, o pré-tratamento com ACP não interfere na eficácia da DBT em elevar a pressão arterial de cavalos anestesiados com ISO.

Comparison of the sedative effects of morphine, meperidine or fentanyl, in combination with acepromazine, in dogs

This study aimed to compare the sedative effects of morphine, meperidine and fentanyl, in combination with acepromazine (ACP) and their effects on physiologic values in dogs. Six healthy beagle dogs were randomly assigned to four treatments with 7-day washout intervals. In three treatments, ACP (0.05mg kg-1) was administered and 20 minutes later, the dogs received administration of 0.5mg kg-1 of morphine (ACPMOR), 5mg kg-1 of meperidine (ACPMEP) or 5µg kg-1 of fentanyl (ACPFEN). In treatment ACP HD MOR, 0.1mg kg-1 of ACP was administered in combination with 0.5mg kg-1 of morphine. All drugs were administered intravenously. Sedation scores were evaluated by a numeric descriptive scale (NDS: 0-3) and a simple numeric scale (SNS: 0-10). All variables were evaluated for 120 minutes. The administration of ACP caused mild to moderate sedation. Sedation was improved in all treatments after opioid administration, but significant differences were detected only in ACPMOR and ACP HD MOR. More dogs presented intense sedation (NDS=3.0) after administration of morphine (3/6 and 4/6 dogs in ACPMOR and ACP HD MOR versus 1/6 in other treatments). Duration of sedation was longer in ACPMOR and ACP HD MOR. Mild to moderate decreases in blood pressure, respiratory rate and temperature were observed in all treatments but decreased HR was observed only in ACPMOR and ACP HD MOR. No significant differences were observed in the aforementioned variables when twice the dose of ACP was used (treatment ACP HD MOR). Under the conditions of this study, administration of morphine, in combination with ACP, results in greater and longer sedation than meperidine and fentanyl. Increasing the dose of ACP, in combination with morphine, does not improve the degree of sedation. All combinations used were considered to be safe for healthy dogs.

O presente estudo objetivou comparar o efeito sedativo da morfina, meperidina e fentanil associados à acepromazina (ACP) e seus efeitos sobre as variáveis fisiológicas de cães. Seis cães Beagle hígidos foram aleatoriamente submetidos a quatro tratamentos com intervalo de 7 dias. Em três tratamentos, foi administrada ACP (0,05mg kg-1) e, após 20 minutos, 0,5mg kg-1 de morfina (ACPMOR), 5mg kg-1 de meperidina (ACPMEP) ou 5µg kg-1 de fentanil (ACPFEN). No tratamento ACP DA MOR, a dose de 0,1mg kg-1 de ACP foi associada a 0,5mg kg-1 de morfina. Todos os fármacos foram administrados pela via IV. Escores de sedação foram avaliados pela escala numérica descritiva (END: 0-3) e escala numérica simples (ENS: 0-10). Todas as variáveis foram avaliadas durante 120 minutos. A administração da ACP causou sedação leve à moderada. A sedação foi intensificada em todos os tratamentos após a administração do opioide, mas diferença significativa foi observada somente em ACPMOR e ACP DA MOR. Um número maior de cães apresentou sedação intensa (END=3,0) após a administração da morfina (3/6 e 4/6 cães em ACPMOR e ACP DA MOR versus 1/6 nos demais tratamentos). A duração do efeito sedativo foi mais longa em ACPMOR e ACP DA MOR. Houve redução leve a moderada na pressão arterial, frequência respiratória e temperatura em todos os tratamentos e redução significativa da frequência cardíaca somente nos tratamentos ACPMOR e ACP DA MOR. Não houve diferenças significativas nas variáveis estudadas quando o dobro da dose de ACP foi utilizada (tratamento ACP DA MOR). Nas condições deste estudo, a administração da morfina, em associação à ACP, resulta em sedação de maior intensidade e duração do que a meperidina e o fentanil. O aumento na dose de ACP, em associação à morfina, não intensifica o grau de sedação. Todas as associações foram consideradas seguras para cães hígidos.

Canine lacrimal and third eyelid superficial glands macroscopic and morphometric characteristics

The lacrimal and third eyelid superficial glands produce the aqueous component of the preocular tear film. In this research, morphologic and morphometric assessments of the parenchyma and stroma of both lacrimal glands of healthy adult mongrel dogs were performed. Both lacrimal and third eyelid glands of fourteen dogs were collected, summing fifty-six samples. The macroscopic and morphometric data were statistically analyzed, according to the glandular type (lacrimal and third eyelid superficial glands) and sexual dimorphism (male or female). The lacrimal glands were significantly larger and longer than the superficial glands of the third eyelid. Expressive morphometric differences of interlobular duct, lymphocytic infiltration, interlobular vessels and secretory parenchyma between the two glandular types were encountered. The lacrimal glands from the male subjects were significantly larger than those from female ones, as well as the superficial glands of the third eyelid were thicker. The higher lymphocyte infiltration and poorer secretor parenchyma in female dogs may be one of the reasons for the higher incidence of keratoconjunctiviti sicca (KCS) in such canine population.

As glândulas lacrimal e superficial da terceira pálpebra atuam produzindo o componente aquoso do filme lacrimal. Nesta pesquisa, estudaram-se aspectos morfológicos e morfométricos do parênquima e do estroma de ambas as glândulas em cães mestiços, hígidos, adultos (machos ou fêmeas). As glândulas lacrimal e superficial da terceira pálpebra de 14 cães foram colhidas, totalizando 56 amostras. Foram estudadas, à estatística, as variáveis macroscópicas e morfométricas, comparando-as quanto ao tipo glandular (lacrimal e superficial da terceira pálpebra) e quanto ao dimorfismo sexual (macho e fêmea). Às glândulas lacrimais foram significativamente maiores comparativamente as superficiais da terceira pálpebra. Foram evidenciados diferenças morfométricas expressivas quanto aos vasos e ductos interlobulares, ducto interlobular, infiltração linfocitária e parênquima secretório entre os dois tipos glandulares. As glândulas lacrimais dos machos foram significativamente maiores comparativamente às fêmeas, assim como as glândulas superficiais da terceira pálpebra apresentaram-se mais espessas. A maior infiltração linfocitária e a menor proporção de parênquima secretor nas fêmeas poderá ser uma das razões para uma maior incidência de ceratoconjuntivite seca (CCS) em fêmeas na população canina.

Canine lacrimal and third eyelid superficial glands’ macroscopic and morphometric characteristics

The lacrimal and third eyelid superficial glands produce the aqueous component of the preocular tear film. In this research, morphologic and morphometric assessments of the parenchyma and stroma of both lacrimal glands of healthy adult mongrel dogs were performed. Both lacrimal and third eyelid glands of fourteen dogs were collected, summing fifty-six samples. The macroscopic and morphometric data were statistically analyzed, according to the glandular type (lacrimal and third eyelid superficial glands) and sexual dimorphism (male or female). The lacrimal glands were significantly larger and longer than the superficial glands of the third eyelid. Expressive morphometric differences of interlobular duct, lymphocytic infiltration, interlobular vessels and secretory parenchyma between the two glandular types were encountered. The lacrimal glands from the male subjects were significantly larger than those from female ones, as well as the superficial glands of the third eyelid were thicker. The higher lymphocyte infiltration and poorer secretor parenchyma in female dogs may be one of the reasons for the higher incidence of keratoconjunctiviti sicca (KCS) in such canine population.

As glândulas lacrimal e superficial da terceira pálpebra atuam produzindo o componente aquoso do filme lacrimal. Nesta pesquisa, estudaram-se aspectos morfológicos e morfométricos do parênquima e do estroma de ambas as glândulas em cães mestiços, hígidos, adultos (machos ou fêmeas). As glândulas lacrimal e superficial da terceira pálpebra de 14 cães foram colhidas, totalizando 56 amostras. Foram estudadas, à estatística, as variáveis macroscópicas e morfométricas, comparando-as quanto ao tipo glandular (lacrimal e superficial da terceira pálpebra) e quanto ao dimorfismo sexual (macho e fêmea). Às glândulas lacrimais foram significativamente maiores comparativamente as superficiais da terceira pálpebra. Foram evidenciados diferenças morfométricas expressivas quanto aos vasos e ductos interlobulares, ducto interlobular, infiltração linfocitária e parênquima secretório entre os dois tipos glandulares. As glândulas lacrimais dos machos foram significativamente maiores comparativamente às fêmeas, assim como as glândulas superficiais da terceira pálpebra apresentaram-se mais espessas. A maior infiltração linfocitária e a menor proporção de parênquima secretor nas fêmeas poderá ser uma das razões para uma maior incidência de ceratoconjuntivite seca (CCS) em fêmeas na população canina.